A Phase II, Randomised, Double Blind Study Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia.

Trial Profile

A Phase II, Randomised, Double Blind Study Assessing the Efficacy of EGb761 120mg Bid Versus Placebo in Patients Suffering From Friedreich Ataxia.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2013

At a glance

  • Drugs EGb 761 (Primary)
  • Indications Friedreich's ataxia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2012 Company added in the association field as reported by ClinicalTrials.gov.
    • 29 Nov 2011 Actual patient number is 22 according to ClinicalTrials.gov.
    • 29 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top